CA2025070A1 - Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique - Google Patents

Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique

Info

Publication number
CA2025070A1
CA2025070A1 CA2025070A CA2025070A CA2025070A1 CA 2025070 A1 CA2025070 A1 CA 2025070A1 CA 2025070 A CA2025070 A CA 2025070A CA 2025070 A CA2025070 A CA 2025070A CA 2025070 A1 CA2025070 A1 CA 2025070A1
Authority
CA
Canada
Prior art keywords
aprotinin variants
homgeneously
genetically engineered
therapeutic use
processed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2025070A
Other languages
English (en)
Other versions
CA2025070C (fr
Inventor
Jurgen Ebbers
Dietrich Horlein
Michael Schedel
Rathindra Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CA2025070A1 publication Critical patent/CA2025070A1/fr
Application granted granted Critical
Publication of CA2025070C publication Critical patent/CA2025070C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002025070A 1989-09-13 1990-09-11 Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique Expired - Fee Related CA2025070C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3930522A DE3930522A1 (de) 1989-09-13 1989-09-13 Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben
DEP3930522.8 1989-09-13

Publications (2)

Publication Number Publication Date
CA2025070A1 true CA2025070A1 (fr) 1991-03-14
CA2025070C CA2025070C (fr) 2001-01-02

Family

ID=6389306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002025070A Expired - Fee Related CA2025070C (fr) 1989-09-13 1990-09-11 Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique

Country Status (15)

Country Link
US (1) US5164482A (fr)
EP (1) EP0419878B1 (fr)
JP (1) JP2916228B2 (fr)
KR (1) KR0169976B1 (fr)
AT (1) ATE113074T1 (fr)
AU (1) AU632361B2 (fr)
CA (1) CA2025070C (fr)
DD (1) DD299311A5 (fr)
DE (2) DE3930522A1 (fr)
DK (1) DK0419878T3 (fr)
ES (1) ES2062235T3 (fr)
FI (1) FI104724B (fr)
HU (1) HU213582B (fr)
IL (1) IL95618A (fr)
ZA (1) ZA907266B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
US5056341A (en) * 1989-06-08 1991-10-15 Sanyo Electric Co., Ltd. Washing machine
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
CA2453264A1 (fr) * 2001-07-10 2003-04-24 Omnio Ab Nouvelles cibles medicamenteuses pour l'arthrite
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
AU2006290733B8 (en) 2005-09-16 2012-07-05 Bayer Intellectual Property Gmbh Transplastomic plants expressing lumen-targeted protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
US5618915A (en) * 1987-08-28 1997-04-08 Novo Nordisk Aprotinin analogs
US5621074A (en) * 1987-08-28 1997-04-15 Novo Nordisk A/S Aprotinin analogs

Also Published As

Publication number Publication date
AU6245390A (en) 1991-03-21
AU632361B2 (en) 1992-12-24
IL95618A (en) 1996-09-12
IL95618A0 (en) 1991-06-30
HUT62031A (en) 1993-03-29
US5164482A (en) 1992-11-17
FI104724B (fi) 2000-03-31
JPH03197496A (ja) 1991-08-28
DK0419878T3 (da) 1994-11-21
ZA907266B (en) 1991-07-31
DE59007498D1 (de) 1994-11-24
EP0419878A1 (fr) 1991-04-03
DE3930522A1 (de) 1991-03-21
ATE113074T1 (de) 1994-11-15
KR910006483A (ko) 1991-04-29
HU905877D0 (en) 1991-03-28
DD299311A5 (de) 1992-04-09
JP2916228B2 (ja) 1999-07-05
KR0169976B1 (ko) 1999-02-01
CA2025070C (fr) 2001-01-02
HU213582B (en) 1997-08-28
FI904474A0 (fi) 1990-09-11
ES2062235T3 (es) 1994-12-16
EP0419878B1 (fr) 1994-10-19

Similar Documents

Publication Publication Date Title
CA2025070A1 (fr) Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique
CA2153584A1 (fr) Agents de restriction de cytokines
CA2066248A1 (fr) Esters d'acides thiophenecarboxyliques et d'aminoalcools; composes quaternaires obtenus par cette voie; production et utilisation de ces substances
EP1234586A3 (fr) Agents hépatosélectifs à activité pharmaceutique
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU2535188A (en) Pharmaceutical compositions of recombinant beta-interferon and formulation processes
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
EP0340333A3 (en) Novel physiologically active polypeptide and pharmaceutical composition
AU635074B2 (en) S(+)-ibuprofen-l-amino acid and s(+)-ibuprofen-d-amino acid as onset hastened enhanced analgesics
AU671881C (en) Novel Process for the Preparation of Lyophilised Peptides
EP0437610A4 (en) Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide
AU2670495A (en) Ifn-beta liquid formulations
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU1377092A (en) Peptides for treatment
EP0369474A3 (fr) Composition pharmaceutique pour le traitement de l'oedème cérébral
CA2011008A1 (fr) Variants du facteur de croissance epidermique et leur utilisation pharmacologique
AU1496888A (en) Biologically active molecules
HUT55598A (en) Fungicidal composition comprising new amino acid amide derivatives as active ingredient and process for producing the active ingredients
HUT49370A (en) Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient
CA2102606A1 (fr) Compositions pour le traitement du syndrome de fatigue chronique
WO2000061176A3 (fr) Traitement combine de la sclerose en plaques
CA2133441A1 (fr) Proteines immunogenes d'haemophilus somnus
AU634584B2 (en) Aroyl-ureas
AU2487192A (en) Expression of enzymatically active recombinant human acetylcholinesterase and uses thereof
HU896610D0 (en) Herbicid composition comprising substituted-sulfonyl-urea as active ingredient and process for preparation thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed